Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow APRE by emailGet an email when APRE pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about APRE, unsubscribe in one click. Privacy
📣 What APRE Says Is Next
Q4 · “The Company expects enrollment to reach 6 to 10 patients per month by Q4 of 2026, potentially increasing the pace of clinical data generation.”
Company press release, Aug 12, 2026 · SEC filing
fourth quarter of 2026 · “Aprea expects to report the next clinical data update from ACESOT-1051 at a medical meeting in the fourth quarter of 2026.”
Company press release, Aug 12, 2026 · SEC filing
in 2026 · “These developments reinforce Aprea’s differentiated DDR approach and our commitment to helping patients with value creating clinical catalysts anticipated in 2026.” Key Business Updates and Potential Upcoming Key Milestones ACESOT-1051: A Biomarker Focused, Phase 1 Trial of Oral WEE1 inhibitor, APR-1051”
Company press release, Nov 12, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full APRE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for APRE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.